NASDAQ : SCYX
SCYNEXIS, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 3.76 USD (Oct 30, 2026, 1:55 PM EDT) · Market cap 37.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 37.51M |
| Enterprise Value | -14.63M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.95M |
| Shares Outstanding | 9.95M |
| Shares Change (YoY) | +25.40% |
| Shares Change (QoQ) | +85.63% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 33.78% |
| Float | 7.35M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.95 |
| Forward PS | 19.59 |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.65 |
| Quick Ratio | 9.28 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -18.38% |
| Return on Assets (ROA) | -20.82% |
| Return on Invested Capital (ROIC) | -152.78% |
| Return on Capital Employed (ROCE) | -32.68% |
| Weighted Average Cost of Capital (WACC) | 9.58% |
| Revenue Per Employee | $1.07M |
| Profits Per Employee | -$568,611 |
| Employee Count | 18 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.06 |
| 52-Week Price Change | -31.39% |
| 50-Day Moving Average | 4.56 |
| 200-Day Moving Average | 5.54 |
| Relative Strength Index (RSI) | 37.83 |
| Average Volume (20 Days) | 110,588 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 420,517 |
| Short Previous Month | 594,318 |
| Short % of Shares Out | 4.23% |
| Short % of Float | 5.72% |
| Short Ratio (days to cover) | 0.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 19.22M |
| Gross Profit | 19.22M |
| Operating Income | -22.60M |
| Pretax Income | -10.24M |
| Net Income | -10.24M |
| EBITDA | n/a |
| EBIT | -22.60M |
| Loss Per Share | -$1.33 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 54.08M |
| Total Debt | 1.95M |
| Net Cash | 52.14M |
| Net Cash Per Share | $5.24 |
| Equity (Book Value) | 66.93M |
| Book Value Per Share | 6.73 |
| Working Capital | 50.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -13.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -13.31M |
| FCF Per Share | -$1.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -117.61% |
| Pretax Margin | -53.26% |
| Profit Margin | -53.26% |
| EBITDA Margin | n/a |
| EBIT Margin | -117.61% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -25.40% |
| Shareholder Yield | -25.40% |
| Earnings Yield | -35.26% |
| FCF Yield | -35.48% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $36.33 |
| Price Target Difference | 863.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -11.91% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 1, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.56 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |